West Pharma (NYSE: WST) reported Q1 EPS of $0.74, $0.09 better than the analyst estimate of $0.65. Revenue for the quarter came in at $443.5 million versus the consensus estimate of $430.67 million.

• Net sales of $443.5 million grew 7%, organic sales growth was 11%
• Reported-diluted EPS of $0.73 increased 26%
• Adjusted-diluted EPS of $0.74 increased 19%
• Repurchased 800,000 shares of common stock for $83.1 million
• Company reaffirms full-year 2019 net sales guidance and raises full-year 2019 adjusted-diluted EPS guidance to a new range between $2.80 and $2.90, compared to a prior range between $2.77 and $2.89.

"Our organization executed on multiple fronts to deliver a strong start to the year, with good growth performance across all segments and market units," said Eric M. Green, President and Chief Executive Officer. "With double-digit organic sales growth in high-value products, coupled with continued execution on Global Operations strategic initiatives, we expanded adjusted operating profit margin by 250 basis points."

GUIDANCE:

West Pharma sees FY2019 EPS of $2.80-$2.90, versus the consensus of $2.86. West Pharma sees FY2019 revenue of $1.795-1.82 million, versus the consensus of $1.81 million.

For earnings history and earnings-related data on West Pharma (WST) click here.